Trial Profile
Phase II Study to Evaluate the Efficacy and Safety of Baricitinib for Reduction of HIV in the Central Nervous System
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 01 Apr 2024 Status changed from suspended to recruiting.
- 19 Sep 2023 Status changed from recruiting to suspended.
- 27 Jun 2023 Status changed from not yet recruiting to recruiting.